Di-cyclopentylmethyl-amin | 3217-97-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Di-cyclopentylmethyl-amin
• 英文别名: N-(Cyclopentylmethyl)cyclopentanemethanamine；1-cyclopentyl-N-(cyclopentylmethyl)methanamine
• CAS: 3217-97-8
• 化学式: C₁₂H₂₃N
• 分子量: 181.321
• InChiKey: WJLMTQQTWWAPRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Di-cyclopentylmethyl-amin 在 盐酸 、 ammonium hexafluorophosphate 作用下， 生成
  参考文献：
  名称：

  轮烷还是假轮烷？就是那个问题！†

  摘要：

  已经制备了一系列仲二烷基铵离子 (RCH2)2NH2+，并评估了它们对大环聚醚二苯并[24]冠-8 (DB24C8) 的结合性能。通过使用这些信息，建立了一条通过 DB24C8 大环和铵中心之间的非共价键相互作用稳定的动力学稳定的轮烷样实体的途径，其中冠醚滑过二烷基铵离子的终止基团 (R)。然而，我们发现这种轮烷状实体的动力学稳定性极其依赖于溶解它的溶剂的性质，这表明假轮烷位于两组极端之间的模糊域中，其中一个珠状大环和一个哑铃状成分可以 (1) 作为轮烷存在或 (2) 彼此完全分离。

  DOI：

  10.1021/ja9731276
• 作为产物：
  描述：

  Bicyclo[3.1.0]hexan-exo-6-amin 生成 Di-cyclopentylmethyl-amin
  参考文献：
  名称：

  ISOGAI, KOJI;SAKAI, JUN-ICHI;YAMAUCHI, KEIJI, J. CHEM. SOC. JAP., CHEM. AND IND. CHEM., 1986, N 2, 214-216

  摘要：

  DOI：

文献信息

• Highly Selective Hydrogenative Conversion of Nitriles into Tertiary, Secondary, and Primary Amines under Flow Reaction Conditions
  作者：Tsuyoshi Yamada、Kwihwan Park、Chikara Furugen、Jing Jiang、Eisho Shimizu、Naoya Ito、Hironao Sajiki

  DOI：10.1002/cssc.202102138

  日期：2022.1.21

  one ain't bad: Various tertiary, secondary, and primary amines are synthesized in moderate to quantitative yield by the hydrogenation of nitriles under flow conditions. This method enables selective synthesis of three different types of amine from one type of nitrile by using commercial Pd/C or Rh/C catalysts and solvents. The catalyst-packed cartridge is continuously used for at least 72 h.

  三选一还不错：通过在流动条件下氢化腈以中等至定量的收率合成各种叔胺、仲胺和伯胺。该方法能够通过使用商业 Pd/C 或 Rh/C 催化剂和溶剂从一种腈选择性合成三种不同类型的胺。填充催化剂的药筒连续使用至少 72 小时。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。
• TISSUE FACTOR PRODUCTION INHIBITOR
  申请人：Sankyo Company, Limited

  公开号：EP1764075A1

  公开（公告）日：2007-03-21

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种具有抑制组织因子生成活性的药物，其活性成分包括一种 LXR 配体；用于治疗和/或预防血管成形术、动脉内膜切除术、经皮腔内冠状动脉成形术（PTCA）或支架植入术后的血管再狭窄，或治疗和/或预防血液凝固疾病、血小板聚集诱发的疾病（包括稳定型或不稳定型心绞痛）的药物、心脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病、溶栓后的再血栓形成、脑缺血发作、脑梗塞、中风、缺血性痴呆、外周动脉疾病、使用主动脉-冠状动脉搭桥过程中的血栓栓塞形成疾病、肾小球硬化、肾栓塞、肿瘤或癌症转移，其活性成分包括 LXR 配体。
• BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1806332A1

  公开（公告）日：2007-07-11

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: -COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: -X2R10 [wherein R10: -COR11 (wherein R11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: -NH-, -O-, -S-, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优异的 LXR 调节剂。由通式（I）代表的化合物： [其中 R1：-COR9（其中 R9：烷基、任选取代的烷氧基或任选取代的氨基）；R2：H、OH、烷氧基、任选取代的氨基等； R3：H、任选取代的烷基、环烷基、任选取代的烷氧基、任选取代的氨基、卤素等； R4 和 R5：H、任选取代的烷基、卤素等。R6和R7：H、烷基；R8：-X2R10[其中 R10：-CORR11（其中 R11：OH、任选取代的烷氧基、任选取代的氨基等）、-SO2R12（其中 R12：任选取代的烷基、任选取代的氨基等）、四唑-5-基等；X2：单键、任选取代的亚烷基等]；X1：-NH-、-O-、-S-等；Y1：任选取代的苯基、任选取代的 5 至 6 元芳香杂环基；Y2：任选取代的芳基、任选取代的杂环基等]等。